Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company report that FDA has accepted the filling of a new drug application for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with Type 2 diabetes.
If granted approval by the FDA, this combination brings together in one tablet the mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor (empagliflozin) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin). SGLT2 inhibitors remove excess glucose through the urine by blocking glucose re-absorption in the kidney. DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose.
Boehringer Ingelheim's linagliptin, marketed as Tradjenta®, was approved by FDA in 2011, and is a once-daily, 5-mg tablet used along with diet and exercise to improve glycemic control in adults with Type II diabetes. Empagliflozin is in Phase III development for treatment of Type II diabetes. .
In January 2011, Boehringer Ingelheim and Eli Lilly and Company formed an alliance in diabetes.
Source: Eli Lilly
.
